202 related articles for article (PubMed ID: 30497977)
1. Ectopic high endothelial venules in pancreatic ductal adenocarcinoma: A unique site for targeted delivery.
Bahmani B; Uehara M; Ordikhani F; Li X; Jiang L; Banouni N; Ichimura T; Kasinath V; Eskandari SK; Annabi N; Bromberg JS; Shultz LD; Greiner DL; Abdi R
EBioMedicine; 2018 Dec; 38():79-88. PubMed ID: 30497977
[TBL] [Abstract][Full Text] [Related]
2. Treatment of pancreatic ductal adenocarcinoma with tumor antigen specific-targeted delivery of paclitaxel loaded PLGA nanoparticles.
Wu ST; Fowler AJ; Garmon CB; Fessler AB; Ogle JD; Grover KR; Allen BC; Williams CD; Zhou R; Yazdanifar M; Ogle CA; Mukherjee P
BMC Cancer; 2018 Apr; 18(1):457. PubMed ID: 29685122
[TBL] [Abstract][Full Text] [Related]
3. Tumor-Specific Delivery of 5-Fluorouracil-Incorporated Epidermal Growth Factor Receptor-Targeted Aptamers as an Efficient Treatment in Pancreatic Ductal Adenocarcinoma Models.
Mahajan UM; Li Q; Alnatsha A; Maas J; Orth M; Maier SH; Peterhansl J; Regel I; Sendler M; Wagh PR; Mishra N; Xue Y; Allawadhi P; Beyer G; Kühn JP; Marshall T; Appel B; Lämmerhirt F; Belka C; Müller S; Weiss FU; Lauber K; Lerch MM; Mayerle J
Gastroenterology; 2021 Sep; 161(3):996-1010.e1. PubMed ID: 34097885
[TBL] [Abstract][Full Text] [Related]
4. Targeted delivery of immune therapeutics to lymph nodes prolongs cardiac allograft survival.
Bahmani B; Uehara M; Jiang L; Ordikhani F; Banouni N; Ichimura T; Solhjou Z; Furtmüller GJ; Brandacher G; Alvarez D; von Andrian UH; Uchimura K; Xu Q; Vohra I; Yilmam OA; Haik Y; Azzi J; Kasinath V; Bromberg JS; McGrath MM; Abdi R
J Clin Invest; 2018 Nov; 128(11):4770-4786. PubMed ID: 30277476
[TBL] [Abstract][Full Text] [Related]
5. Interleukin 35 Expression Correlates With Microvessel Density in Pancreatic Ductal Adenocarcinoma, Recruits Monocytes, and Promotes Growth and Angiogenesis of Xenograft Tumors in Mice.
Huang C; Li Z; Li N; Li Y; Chang A; Zhao T; Wang X; Wang H; Gao S; Yang S; Hao J; Ren H
Gastroenterology; 2018 Feb; 154(3):675-688. PubMed ID: 28989066
[TBL] [Abstract][Full Text] [Related]
6. Nanotechnology-Based Strategy for Enhancing Therapeutic Efficacy in Pancreatic Cancer: Receptor-Targeted Drug Delivery by Somatostatin Analog.
Gu X; Majumder J; Taratula O; Kuzmov A; Garbuzenko O; Pogrebnyak N; Minko T
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791582
[TBL] [Abstract][Full Text] [Related]
7. A tunable delivery platform to provide local chemotherapy for pancreatic ductal adenocarcinoma.
Indolfi L; Ligorio M; Ting DT; Xega K; Tzafriri AR; Bersani F; Aceto N; Thapar V; Fuchs BC; Deshpande V; Baker AB; Ferrone CR; Haber DA; Langer R; Clark JW; Edelman ER
Biomaterials; 2016 Jul; 93():71-82. PubMed ID: 27082874
[TBL] [Abstract][Full Text] [Related]
8. The anti-fibrotic effect of GV1001 combined with gemcitabine on treatment of pancreatic ductal adenocarcinoma.
Park JK; Kim Y; Kim H; Jeon J; Kim TW; Park JH; Hwnag YI; Lee WJ; Kang JS
Oncotarget; 2016 Nov; 7(46):75081-75093. PubMed ID: 27655706
[TBL] [Abstract][Full Text] [Related]
9. Self-Assembled Gemcitabine Prodrug Nanoparticles Show Enhanced Efficacy against Patient-Derived Pancreatic Ductal Adenocarcinoma.
Wu L; Zhang F; Chen X; Wan J; Wang Y; Li T; Wang H
ACS Appl Mater Interfaces; 2020 Jan; 12(3):3327-3340. PubMed ID: 31872760
[TBL] [Abstract][Full Text] [Related]
10. Cotargeting of MEK and PDGFR/STAT3 Pathways to Treat Pancreatic Ductal Adenocarcinoma.
Sahu N; Chan E; Chu F; Pham T; Koeppen H; Forrest W; Merchant M; Settleman J
Mol Cancer Ther; 2017 Sep; 16(9):1729-1738. PubMed ID: 28619758
[TBL] [Abstract][Full Text] [Related]
11. Verteporfin suppresses cell survival, angiogenesis and vasculogenic mimicry of pancreatic ductal adenocarcinoma via disrupting the YAP-TEAD complex.
Wei H; Wang F; Wang Y; Li T; Xiu P; Zhong J; Sun X; Li J
Cancer Sci; 2017 Mar; 108(3):478-487. PubMed ID: 28002618
[TBL] [Abstract][Full Text] [Related]
12. The BET inhibitor JQ1 attenuates double-strand break repair and sensitizes models of pancreatic ductal adenocarcinoma to PARP inhibitors.
Miller AL; Fehling SC; Garcia PL; Gamblin TL; Council LN; van Waardenburg RCAM; Yang ES; Bradner JE; Yoon KJ
EBioMedicine; 2019 Jun; 44():419-430. PubMed ID: 31126889
[TBL] [Abstract][Full Text] [Related]
13. Microspheres Encapsulating Immunotherapy Agents Target the Tumor-Draining Lymph Node in Pancreatic Ductal Adenocarcinoma.
Han BJ; Murphy JD; Qin S; Ye J; Uccello TP; Garrett-Larsen J; Belt BA; Prieto PA; Egilmez NK; Lord EM; Linehan DC; Mills BN; Gerber SA
Immunol Invest; 2020 Oct; 49(7):808-823. PubMed ID: 32498585
[TBL] [Abstract][Full Text] [Related]
14. Inhibiting tumor necrosis factor-alpha diminishes desmoplasia and inflammation to overcome chemoresistance in pancreatic ductal adenocarcinoma.
Zhao X; Fan W; Xu Z; Chen H; He Y; Yang G; Yang G; Hu H; Tang S; Wang P; Zhang Z; Xu P; Yu M
Oncotarget; 2016 Dec; 7(49):81110-81122. PubMed ID: 27835602
[TBL] [Abstract][Full Text] [Related]
15. Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma.
Borsoi C; Leonard F; Lee Y; Zaid M; Elganainy D; Alexander JF; Kai M; Liu YT; Kang Y; Liu X; Koay EJ; Ferrari M; Godin B; Yokoi K
Cancer Lett; 2017 Sep; 403():296-304. PubMed ID: 28687352
[TBL] [Abstract][Full Text] [Related]
16. Novel agents for pancreatic ductal adenocarcinoma: emerging therapeutics and future directions.
Zhang Y; Yang C; Cheng H; Fan Z; Huang Q; Lu Y; Fan K; Luo G; Jin K; Wang Z; Liu C; Yu X
J Hematol Oncol; 2018 Jan; 11(1):14. PubMed ID: 29386069
[TBL] [Abstract][Full Text] [Related]
17. Preclinical pharmacodynamic evaluation of a new Src/FOSL1 inhibitor, LY-1816, in pancreatic ductal adenocarcinoma.
Yang W; Meng L; Chen K; Tian C; Peng B; Zhong L; Zhang C; Yang X; Zou J; Yang S; Li L
Cancer Sci; 2019 Apr; 110(4):1408-1419. PubMed ID: 30618127
[TBL] [Abstract][Full Text] [Related]
18. Increased fibrosis and impaired intratumoral accumulation of macromolecules in a murine model of pancreatic cancer co-administered with FGF-2.
Sakai S; Iwata C; Tanaka HY; Cabral H; Morishita Y; Miyazono K; Kano MR
J Control Release; 2016 May; 230():109-15. PubMed ID: 27080571
[TBL] [Abstract][Full Text] [Related]
19. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.
Nagathihalli NS; Castellanos JA; Shi C; Beesetty Y; Reyzer ML; Caprioli R; Chen X; Walsh AJ; Skala MC; Moses HL; Merchant NB
Gastroenterology; 2015 Dec; 149(7):1932-1943.e9. PubMed ID: 26255562
[TBL] [Abstract][Full Text] [Related]
20. Induction of cell death in pancreatic ductal adenocarcinoma by indirubin 3'-oxime and 5-methoxyindirubin 3'-oxime in vitro and in vivo.
Sano M; Ichimaru Y; Kurita M; Hayashi E; Homma T; Saito H; Masuda S; Nemoto N; Hemmi A; Suzuki T; Miyairi S; Hao H
Cancer Lett; 2017 Jul; 397():72-82. PubMed ID: 28347789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
